NCT01887535View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Healthy
Interventions
DRUG

JNJ-54861911 3 mg

JNJ-54861911 3 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 10 mg

JNJ-54861911 10 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 30 mg

JNJ-54861911 30 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 80 mg

JNJ-54861911 80 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 25 mg

JNJ-54861911 25 mg will be administered as a solid dose formulation.

DRUG

Placebo

Matching placebo will be administered as an oral suspension formulation.

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01887535 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants | Biotech Hunter | Biotech Hunter